Literature DB >> 18294275

Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma.

Takashi Imai1, Minoru Toyota, Hiromu Suzuki, Kimishige Akino, Kazuhiro Ogi, Yohei Sogabe, Lisa Kashima, Reo Maruyama, Masanori Nojima, Hiroaki Mita, Yasushi Sasaki, Fumio Itoh, Kohzoh Imai, Yasuhisa Shinomura, Hiroyoshi Hiratsuka, Takashi Tokino.   

Abstract

Genetic and epigenetic alterations in tumor-suppressor genes play important roles in human neoplasia. Ras signaling is often activated in oral squamous cell carcinoma (OSCC), although Ras mutations are rarely detected in Japanese OSCC patients, and the mechanisms underlying the gene's activation remain unclear. Here, we examined the expression of Ras association family (RASSF) genes in a panel of OSCC cell lines and found that RASSF2 is often downregulated by DNA methylation in OSCC cells. In addition, aberrant methylation of RASSF2 was detected in 12 of 46 (26%) primary OSCC, and 18 (39%) of those OSCC showed methylation of at least one RASSF gene. Ectopic expression of RASSF2 in OSCC cells suppressed cell growth and induced apoptosis. A RASSF2 deletion mutant lacking the Ras-association domain, which was therefore unable to interact with Ras, exhibited less pro-apoptotic activity than the full-length protein, indicating that the pro-apoptotic activity of RASSF2 is related to its association with Ras. Genomic screening of genes regulated by RASSF2 showed that genes involved in immune responses, angiogenesis, and metastasis are suppressed by RASSF2. Our results suggest that epigenetic inactivation of RASSF2 plays an important role in OSCC tumorigenesis, and that RASSF2 may be a useful molecular target for the diagnosis and treatment of OSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294275     DOI: 10.1111/j.1349-7006.2008.00769.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  24 in total

1.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

2.  Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.

Authors:  D Aydin; A Bilici; S Kayahan; D Yavuzer; M Basar; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

3.  RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level.

Authors:  Jinghua Ren; Wenshan He; Ruiguang Zhang; Zhenyu Li; Wenmiao Cao; Jie Yao; Fang Zhu; Tao Zhang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 4.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

5.  The Ras effector RASSF2 controls the PAR-4 tumor suppressor.

Authors:  Howard Donninger; Luke Hesson; Michele Vos; Kristin Beebe; Laura Gordon; David Sidransky; Jun Wei Liu; Thomas Schlegel; Shannon Payne; Arndt Hartmann; Farida Latif; Geoffrey J Clark
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

6.  Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.

Authors:  Neema Jamshidi; Maximilian Diehn; Markus Bredel; Michael D Kuo
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

7.  Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer.

Authors:  Xiaoliang Wang; Chongzhi Zhou; Guoqiang Qiu; Yinxue Yang; Dongwang Yan; Tonghai Xing; Junwei Fan; Huamei Tang; Zhihai Peng
Journal:  Med Oncol       Date:  2011-06-11       Impact factor: 3.064

8.  RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.

Authors:  Seley Gharanei; Anna T Brini; Sumathi Vaiyapuri; Abdullah Alholle; Ashraf Dallol; Elena Arrigoni; Takeshi Kishida; Toru Hiruma; Smadar Avigad; Robert Grimer; Eamonn R Maher; Farida Latif
Journal:  Epigenetics       Date:  2013-07-18       Impact factor: 4.528

9.  Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients.

Authors:  Deng Luo; Ting Ye; Tian-Qian Li; Peng Tang; Sha-Dong Min; Gong-Fang Zhao; Hua Huang; Jiang Chang; Yan Wang; Lin Lv; Ming-Liang Lu; Meng-Yao Zheng
Journal:  Exp Ther Med       Date:  2011-12-28       Impact factor: 2.447

10.  Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation.

Authors:  Emanuela Taioli; Camille Ragin; Xiao-Hong Wang; Jiangying Chen; Scott M Langevin; Ashley R Brown; Susanne M Gollin; Seymour Garte; Robert W Sobol
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.